{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:10:28Z","timestamp":1792188628267,"version":"4.4.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.endien.2024.03.012","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T11:53:03Z","timestamp":1711626783000},"page":"124-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5620-6468","authenticated-orcid":false,"given":"Walter","family":"Masson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Barbagelata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Lavalle-Cobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan P.","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.endien.2024.03.012_bib0275","first-page":"e45487","article-title":"Role of glucagon-like peptide-1 (GLP-1) receptor agonists in cardiovascular risk management in patients with type 2 diabetes mellitus: a systematic review","volume":"15","author":"Parab","year":"2023","journal-title":"Cureus"},{"issue":"Suppl. 1","key":"10.1016\/j.endien.2024.03.012_bib0280","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/dom.15043","article-title":"Effects of glucagon-like peptide-1 receptor agonists on major coronary events in patients with type 2 diabetes","volume":"25","author":"Guo","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endien.2024.03.012_bib0285","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.endien.2024.03.012_bib0290","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s13300-023-01506-1","article-title":"Potential new therapeutic implications of semaglutide: new colours of the rainbow?","volume":"15","author":"Gouveri","year":"2024","journal-title":"Diabetes Ther"},{"issue":"sup1","key":"10.1016\/j.endien.2024.03.012_bib0295","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/00325481.2022.2147326","article-title":"Efficacy and safety of semaglutide for weight management: evidence from the STEP program","volume":"134","author":"Amaro","year":"2022","journal-title":"Postgrad Med"},{"key":"10.1016\/j.endien.2024.03.012_bib0300","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2024.03.012_bib0305","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0140-6736(20)31310-6","article-title":"Acute pancreatitis","volume":"396","author":"Boxhoorn","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.endien.2024.03.012_bib0310","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/postgradmedj-2018-136034","article-title":"Acute management of pancreatitis: the key to best outcomes","volume":"95","author":"Olson","year":"2019","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.endien.2024.03.012_bib0315","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.diabres.2014.01.010","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials","volume":"103","author":"Monami","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.endien.2024.03.012_bib0320","doi-asserted-by":"crossref","first-page":"645563","DOI":"10.3389\/fendo.2021.645563","article-title":"Safety of semaglutide","volume":"12","author":"Smits","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.endien.2024.03.012_bib0325","first-page":"206","article-title":"Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials","volume":"48","author":"Nreu","year":"2023","journal-title":"Minerva Endocrinol (Torino)"},{"key":"10.1016\/j.endien.2024.03.012_bib0330","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.endien.2024.03.012_bib0335","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"28","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.endien.2024.03.012_bib0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metaphor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Soft"},{"key":"10.1016\/j.endien.2024.03.012_bib0345","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endien.2024.03.012_bib0350","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.endien.2024.03.012_bib0355","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","article-title":"Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.endien.2024.03.012_bib0360","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"38","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2024.03.012_bib0365","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 Trial","volume":"42","author":"Zinman","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endien.2024.03.012_bib0370","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S2213-8587(20)30075-9","article-title":"Dose\u2013response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2\/3a, randomised, controlled trial","volume":"8","author":"Yamada","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.endien.2024.03.012_bib0375","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.endien.2024.03.012_bib0380","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.endien.2024.03.012_bib0385","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.endien.2024.03.012_bib0390","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.endien.2024.03.012_bib0395","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2024.03.012_bib0400","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.endien.2024.03.012_bib0405","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2024.03.012_bib0410","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.endien.2024.03.012_bib0415","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.endien.2024.03.012_bib0420","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.endien.2024.03.012_bib0425","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.endien.2024.03.012_bib0430","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.endien.2024.03.012_bib0435","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2024.03.012_bib0440","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.endien.2024.03.012_bib0445","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endien.2024.03.012_bib0450","first-page":"45","article-title":"Drug-induced acute pancreatitis: a review","volume":"15","author":"Jones","year":"2015","journal-title":"Ochsner J"},{"key":"10.1016\/j.endien.2024.03.012_bib0455","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.endien.2024.03.012_bib0460","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00125-009-1515-4","article-title":"Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas","volume":"53","author":"Nachnani","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.endien.2024.03.012_bib0465","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.endien.2024.03.012_bib0470","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1463-1326.2011.01376.x","article-title":"A cohort study of acute pancreatitis in relation to exenatide use","volume":"13","author":"Dore","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.endien.2024.03.012_bib0475","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.2337\/dc10-0482","article-title":"Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis","volume":"33","author":"Garg","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endien.2024.03.012_bib0480","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S2213-8587(13)70147-5","article-title":"Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case\u2013control study","volume":"2","author":"Giorda","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.endien.2024.03.012_bib0485","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case\u2013control study","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.endien.2024.03.012_bib0490","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s11695-008-9599-3","article-title":"Obesity, pancreatitis, and pancreatic cancer","volume":"18","author":"Gumbs","year":"2008","journal-title":"Obes Surg"},{"key":"10.1016\/j.endien.2024.03.012_bib0495","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13098-023-01086-x","article-title":"Association between glycemic status and the risk of acute pancreatitis: a nationwide population-based study","volume":"15","author":"Cho","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.endien.2024.03.012_bib0500","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s12020-020-02223-6","article-title":"GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials","volume":"68","author":"Cao","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.endien.2024.03.012_bib0505","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3390\/biomedicines11030667","article-title":"The cause and effect relationship of diabetes after acute pancreatitis","volume":"11","author":"\u015aliwi\u0144ska-Mosso\u0144","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.endien.2024.03.012_bib0510","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1177\/1060028019889064","article-title":"Oral semaglutide: first-in-class oral GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus","volume":"54","author":"Cowart","year":"2020","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.endien.2024.03.012_bib0515","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40262-020-00951-6","article-title":"Pharmacokinetics and clinical implications of oral semaglutide for type 2 diabetes mellitus","volume":"60","author":"Clements","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.endien.2024.03.012_bib0520","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.3748\/wjg.v29.i37.5268","article-title":"Acute pancreatitis: a review of diagnosis, severity prediction and prognosis assessment from imaging technology, scoring system and artificial intelligence","volume":"29","author":"Hu","year":"2023","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.endien.2024.03.012_bib0525","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4158\/EP11290.OR","article-title":"Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting","volume":"18","author":"Lando","year":"2012","journal-title":"Endocr Pract"},{"key":"10.1016\/j.endien.2024.03.012_bib0530","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/dme.13160","article-title":"Acute plasma amylase increase after glucagon-like peptide-1 receptor agonist exenatide administration in type 2 diabetes","volume":"34","author":"Smits","year":"2017","journal-title":"Diabetes Med"},{"key":"10.1016\/j.endien.2024.03.012_bib0535","doi-asserted-by":"crossref","first-page":"966","DOI":"10.2337\/dc16-2747","article-title":"Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with liraglutide: results from the LEADER randomized trial","volume":"40","author":"Steinberg","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.endien.2024.03.012_bib0540","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2337\/dc16-2684","article-title":"Impact of liraglutide on amylase, lipase, and acute pancreatitis in participants with overweight\/obesity and normoglycemia, prediabetes, or type 2 diabetes: secondary analyses of pooled data from the SCALE Clinical Development Program","volume":"40","author":"Steinberg","year":"2017","journal-title":"Diabetes Care"}],"container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018024000295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018024000295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T23:53:28Z","timestamp":1715990008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2530018024000295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2530018024000295"],"URL":"https:\/\/doi.org\/10.1016\/j.endien.2024.03.012","relation":{},"ISSN":["2530-0180"],"issn-type":[{"value":"2530-0180","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.endien.2024.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 SEEN and SED. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}